GlassScriptPhysician profile
Kevin W Johnston
NPI 1194122267
$3,172.75
in general payments reported to CMS, 2019-2025
24 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,381 · 2022: $558 · 2023: $734 · 2024: $103 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.65 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.95 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $645.25 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $590.81 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $213.12 | 2021-2023 | |
| Abbvie INC. | $204.52 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $117.88 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $81.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.47 | 2021 | |
| Daiichi Sankyo INC. | $72.87 | 2021 | |
| Amgen INC. | $63.35 | 2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.76 | 2021 | |
| Merck Sharp & Dohme LLC | $46.28 | 2021 | |
| Amarin Pharma, INC. | $45.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $38.31 | 2023 | |
| Esperion Therapeutics, INC. | $36.06 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.96 | 2022 | |
| Almatica Pharma LLC | $28.32 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Kowa Pharmaceuticals America, INC. | $24.03 | 2021 | |
| Astellas Pharma US INC | $23.20 | 2023 | Veozah |
| Scilex Pharmaceuticals INC. | $20.52 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.34 | 2023 | Voquezna |
| Redhill Biopharma INC. | $20.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.23 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.